# US 2013/0261085 A1 · Method of improving response to chemotherapy by administering a phospholipid together with chemotherapeutic agents, and formulations therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0261085 A1
- Document ID: US20130261085A1
- Status: Published application
- Kind: A1
- Application number: 13/541,011
- Filed: 2012-07-03
- Published: 2013-10-03
- Earliest claimed: 2012-03-28
- Inventors: Robert L. Saxe
- Web page: https://patentgrep.com/patent/US20130261085A1

## CPC

- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and formulations for improving efficacy of chemotherapeutic treatment. The formulation includes at least one chemotherapeutic agent and at least one phospholipid or a material comprising the same. The phospholipid facilitates entry of the at least one chemotherapeutic agent into cells of an afflicted individual. A sufficient dosage of a blood-thinning agent is optionally included to mitigate risk of developing blood clots attributable to administration of the chemotherapeutic agent(s). The chemotherapeutic agent(s) and the phospholipid(s), or the material containing the phospholipid(s), are administered in any order but in sufficient time proximity to one another such that the effect of the phospholipid(s) of facilitating entry of the chemotherapeutic agent(s) into the cells at least partially overlaps with the therapeutic effect of the chemotherapeutic agent(s).

## Claims

### Claim 1

A method for improving efficacy of a chemotherapeutic treatment of a disease or condition, wherein the method comprises:
(a) administering a therapeutic amount of at least one chemotherapeutic agent to an individual afflicted with a disease or condition that is treatable by said at least one agent; and
(b) also administering to the individual at least one phospholipid or a material containing at least one said phospholipid, wherein said at least one phospholipid is administered in an amount sufficient to facilitate entry of said at least one chemotherapeutic agent into cells of said individual negatively affected by the disease or condition,
wherein steps (a) and (b) are performed in any order, but in sufficient time proximity such that the effect of the at least one phospholipid in facilitating entry of said at least one chemotherapeutic agent into cells of said afflicted individual at least partially overlaps with the therapeutic effect of said at least one chemotherapeutic agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the material containing said at least one phospholipid is lecithin.

### Claim 3 (depends on 1)

The method of claim 1, wherein the disease or condition is a cancer susceptible to treatment by said at least one chemotherapeutic agent.

### Claim 4 (depends on 3)

The method of claim 3, wherein the cancer is a hematological malignancy.

### Claim 5 (depends on 4)

The method of claim 4, wherein the hematological malignancy is multiple myeloma.

### Claim 6 (depends on 1)

The method of claim 1, which further comprises administering a sufficient dosage of a blood-thinning agent to said individual to mitigate risk of developing blood clots attributable to administration of the at least one chemotherapeutic agent.

### Claim 7 (depends on 6)

The method of claim 6, wherein the blood-thinning agent is aspirin or pycnogenol.

### Claim 8 (depends on 1)

The method of claim 1, wherein the at least one phospholipid or the material containing said at least one phospholipid is combined with the at least one chemotherapeutic agent in a dosage form selected from the group consisting of tablets, capsules, vegetable capsules, an injectable, a trans-dermal patch and liquid solutions formulated for drinking or for infusion.

### Claim 9 (depends on 6)

The method of claim 6, wherein the at least one phospholipid or the material containing said at least one phospholipid is combined with the at least one chemotherapeutic agent and the blood-thinning agent in a dosage form selected from the group consisting of tablets, capsules, vegetable capsules, an injectable, a trans-dermal patch and liquid solutions formulated for drinking or for infusion.

### Claim 10

A method for improving efficacy of a chemotherapeutic treatment of a disease or condition, wherein the method comprises:
(a) administering a therapeutic amount of at least one chemotherapeutic agent to an individual afflicted with a disease or a condition that is treatable by said at least one agent;
(b) also administering to the individual at least one phospholipid or a material containing at least one said phospholipid, wherein the at least one phospholipid is administered in an amount sufficient to facilitate entry of said at least one chemotherapeutic agent into cells of said individual negatively affected by the disease or condition; and
(c) further administering a sufficient dosage of a blood-thinning agent to the individual to mitigate risk of developing blood clots attributable to administration of the at least one chemotherapeutic agent,
wherein steps (a), (b) and (c) are performed in any order but in sufficient time proximity such that the effect of the at least one phospholipid in facilitating entry of said at least one chemotherapeutic agent into cells of said afflicted individual at least partially overlaps with the therapeutic effect of said at least one chemotherapeutic agent.

### Claim 11 (depends on 10)

The method of claim 10, wherein the material containing at least one said phospholipid is lecithin.

### Claim 12 (depends on 11)

The method of claim 11, wherein the disease or condition is a cancer susceptible to treatment by said at least one chemotherapeutic agent.

### Claim 13 (depends on 12)

The method of claim 12, wherein the cancer is a hematological malignancy.

### Claim 14 (depends on 13)

The method of claim 13, wherein the hematological malignancy is multiple myeloma.

### Claim 15 (depends on 10)

The method of claim 10, wherein the blood-thinning agent is aspirin or pycnogenol.

### Claim 16 (depends on 10)

The method of claim 10, wherein the at least one phospholipid or the material containing said at least one phospholipid is combined with the at least one chemotherapeutic agent and the blood-thinning agent in a dosage form selected from the group consisting of tablets, capsules, vegetable capsules, an injectable, a trans-dermal patch and liquid solutions formulated for drinking or for infusion.

### Claim 17

A formulation that improves efficacy of chemotherapeutic treatment of an individual afflicted with a condition or a disease treatable with one or more chemotherapeutic agents, said formulation comprising:
(a) at least one chemotherapeutic agent capable of treating a disease or condition with which said individual is afflicted; and
(b) at least one phospholipid or a material containing at least one said phospholipid, wherein the at least one phospholipid acts to facilitate entry of the at least one chemotherapeutic agent into cells of said individual,
wherein the at least one chemotherapeutic agent and the at least one phospholipid or the material containing said at least one phospholipid are administered in any order, but in sufficient time proximity such that the effect of the at least one phospholipid of facilitating entry of said at least one chemotherapeutic agent into cells of said afflicted individual at least partially overlaps with the therapeutic effect of said at least one chemotherapeutic agent.

### Claim 18 (depends on 17)

The formulation of claim 17, wherein the material containing said at least one phospholipid is lecithin.

### Claim 19 (depends on 17)

The formulation of claim 17, further comprising a blood-thinning agent.

### Claim 20 (depends on 19)

The formulation of claim 19, wherein the blood-thinning agent is aspirin or pycnogenol.

### Claim 21 (depends on 17)

The formulation of claim 17, wherein said formulation is provided in a dosage form selected from the group consisting of tablets, capsules, vegetable capsules, an injectable, a trans-dermal patch and liquid solutions formulated for drinking or for infusion.

### Claim 22

A formulation that improves efficacy of chemotherapeutic treatment of an individual afflicted with a condition or a disease treatable with one or more chemotherapeutic agents, said formulation comprising:
(a) at least one chemotherapeutic agent capable of treating a disease or condition with which said individual is afflicted;
(b) at least one phospholipid or a material containing said at least one phospholipid, wherein the at least one phospholipid acts to facilitate entry of the at least one chemotherapeutic agent into cells of said individual; and
(c) a sufficient dosage of a blood-thinning agent to mitigate risk to the individual of developing blood clots attributable to administration of the at least one chemotherapeutic agent,
wherein the at least one chemotherapeutic agent and the at least one phospholipid or the material containing said at least one phospholipid are administered in any order, but in sufficient time proximity such that the effect of the at least one phospholipid of facilitating entry of said at least one chemotherapeutic agent into cells of said afflicted individual at least partially overlaps with the therapeutic effect of said at least one chemotherapeutic agent.

### Claim 23 (depends on 22)

The formulation of claim 22, wherein the material containing said at least one phospholipid is lecithin.
